|

Vitamin D for Prostate Endocrine Therapy

RECRUITINGPhase 3Sponsored by University of Rochester
Actively Recruiting
PhasePhase 3
SponsorUniversity of Rochester
Started2023-12-14
Est. completion2029-04-29
Eligibility
Age50 Years+
SexMALE
Healthy vol.Accepted
Locations51 sites

Summary

This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that the body needs to grow and develop normally. Vitamin D helps the body absorb calcium. Calcium is one of the main building blocks of bone. A lack of vitamin D can lead to bone diseases such as osteoporosis or rickets. This trial may help researchers determine if high-dose vitamin D helps keep bones strong, lowers number of falls, and lessens fatigue in men getting androgen-deprivation therapy.

Eligibility

Age: 50 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Be diagnosed with Stage I-IV prostate cancer without metastases to bone (lymph node involvement and prior diagnosis of a primary cancer is allowed)
* Be age 50 years or older
* Be starting ADT or have received their first ADT treatment in the past 6 months, with a total of at least 6 planned months of treatment (both luteinizing hormone-releasing hormone \[LHRH\] antagonists and LHRH agonists are permitted)
* Have a total serum vitamin D between 10 and 32 ng/ml
* Have a total serum calcium of less than or equal to 10.5 mg/dl
* Have a normal GFR (glomerular filtration rate \> 30ml)
* Agree not to take calcium and/or vitamin D supplements for the duration of the intervention other than those provided by the study
* Be able to provide written informed consent
* Be able to swallow pills and capsules
* Be able to speak and read English

Exclusion Criteria:

* Have long term (greater than 3 months) use of any pharmacologic bone-modifying agent including but not limited to oral or intravenous (IV) bisphosphonates, denosumab, or teriparatide prior to enrollment
* Have a diagnosis of stage IV chronic kidney disease
* Have a diagnosis of grade II or greater hypercalcemia (serum calcium greater than 11.5 mg/dl)
* Have a history of hypercalcemia or vitamin D toxicity/sensitivity

Conditions5

CancerStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8

Locations51 sites

Helen F Graham Cancer Center
Newark, Delaware, 19713
Site Public Contact302-623-4450lbarone@christianacare.org
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Site Public Contact302-623-4450lbarone@christianacare.org
Carle at The Riverfront
Danville, Illinois, 61832
Site Public Contact800-446-5532Research@Carle.com
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Site Public Contact217-876-4762morganthaler.jodi@mhsil.com
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Site Public Contact800-446-5532Research@carle.com

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.